Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26324 ↗At a glance
Übersichtsarbeit in Pediatric Pulmonology, 2023. Written by Eunice Stiboy and 6 co-authors. Institution: School of Public Health, The University of Sydney, Camperdown, Australia. Major MEDLINE topics: Antibodies, Monoclonal, Respiratory Syncytial Virus Infections. Cited 4 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Uniformity and compliance with clinical practice guidelines (CPGs) for use of palivizumab in preventing severe respiratory syncytial viral infection in Australian high‐risk infants remain unclear.
Methods
An online survey was conducted across the Australian and New Zealand Neonatal Network (ANZNN) to determine clinical practices around palivizumab. A literature search was also performed to identify and compare national and international guidelines.
Results
A total of 65 of 422 ANZNN members completed the survey. Respondents included 61 senior medical staff of consultants/staff specialists (78%) and four nursing staff (6%). According to the survey, infants most likely to be recommended palivizumab included preterm infants born
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Public Health, The University of Sydney, Camperdown, Australia.
- UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.
- National Center for Epidemiology and Population Health, ANU, Canberra, Australia.
- Chidlren's Hospital Westmead Clinical School, The University of Sydney, Camperdown, Australia.
- Susan Wakil School of Nursing and Midwifery, The University of Sydney, Camperdown, Australia.
- Australian and New Zealand Neonatal Network, UNSW, Sydney, Sydney, Australia.
ORCID profiles: Eunice Stiboy, Mei Chan, Gemma L Saravanos, Nusrat Homaira
Cite
APA
Stiboy, E., Chan, M., Islam, M. S., Saravanos, G. L., Lui, K., Jaffe, A., & Homaira, N. (2023). Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26324
Vancouver
Stiboy E, Chan M, Islam MS, Saravanos GL, Lui K, Jaffe A, et al. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26324
BibTeX
@article{Stiboy2023,
author = {Stiboy, Eunice and Chan, Mei and Islam, Md Saiful and Saravanos, Gemma L and Lui, Kei and Jaffe, Adam and Homaira, Nusrat},
title = {Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26324}
}
EUVIMED